Pharmacogenomics of lipid-lowering therapies

Pharmacogenomics

Volumn 14, Issue 8, 2013, Pages 981-995

  Hu, Miao ^a   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cardiovascular disease; fibrates; genetic polymorphisms; low density lipoprotein cholesterol; pharmacogenomics; statins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; C REACTIVE PROTEIN; CERIVASTATIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; ORGANIC ANION TRANSPORTER 2; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

APOE GENE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; GAIN OF FUNCTION MUTATION; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HMGCR GENE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KIF6 GENE; LOSS OF FUNCTION MUTATION; MYALGIA; MYOPATHY; NPC1L1 GENE; PCSK9 GENE; PHARMACODYNAMICS; PHARMACOGENOMICS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; PHARMACOGENETICS; RISK FACTORS;

EID: 84878866053     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.71     Document Type: Review

References (111)

1. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298(7), 786-798 (2007). (Pubitemid 47263161)
2. Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375(9726), 1634-1639 (2010).
3. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31(23), 2844-2853 (2010).
4. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380(9841), 572-580 (2012).
5. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670-1681 (2010).
6. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
7. Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841), 581-590 (2012).
8. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol. Rev. 18(6), 298-304 (2010).
9. Hu M, Mak VWL, Chu TTY, Waye MMY, Tomlinson B. Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr. Pharmacogenomics Pers. Med. 7(1), 1-26 (2009).
10. Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann. Med. 44(5), 419-432 (2012).
11. Postmus I, Verschuren JJ, De Craen AJ et al. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics 13(7), 831-840 (2012).
12. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 6(6), 360-374 (2006). (Pubitemid 44811531)
13. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565-581 (2006). (Pubitemid 44908269)
14. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet. 47(7), 463-474 (2008). (Pubitemid 351861958)
15. Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin. Pharmacol. Ther. 92(5), 584-598 (2012).
16. Hu M, Mak VW, Xiao Y, Tomlinson B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics 14(1), 25-34 (2013).
17. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
18. Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12), 861-866 (2011).
19. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 10(1), 1-11 (2010).
20. Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin. Drug Metab. Toxicol. 7(1), 49-62 (2011).
21. Rodrigues AC. Efflux and uptake transporters as determinants of statin response. Expert Opin. Drug Metab. Toxicol. 6(5), 621-632 (2010).
22. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63(1), 157-181 (2011).
23. Nezasa K, Higaki K, Matsumura T et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos. 30(11), 1158-1163 (2002). (Pubitemid 35265820)
24. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87(1), 130-133 (2010).
25. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
26. Donnelly LA, Doney AS, Tavendale R et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with Type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther. 89(2), 210-216 (2011).
27. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1 5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609-1616 (2009).
28. Elhayany A, Mishaal RA, Vinker S. Is there clinical benefit to routine enzyme testing of patients on statins Expert Opin. Drug Saf. 11(2), 185-190 (2012).
29. Brunham LR, Lansberg PJ, Zhang L et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3), 233-237 (2012).
30. Santos PC, Gagliardi AC, Miname MH et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur. J. Clin. Pharmacol. 68(3), 273-279 (2012).
31. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10(10), 1617-1624 (2009).
32. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86(2), 197-203 (2009).
33. Hu M, Lui SS, Mak VW et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet. Genomics 20(10), 634-637 (2010).
34. Tomlinson B, Hu M, Lee VW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther. 87(5), 558-562 (2010).
35. Bailey KM, Romaine SP, Jackson BM et al. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circ. Cardiovasc. Genet. 3(3), 276-285 (2010).
36. Zhang W, Yu BN, He YJ et al. Role of BCRP 421CA polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373(1-2), 99-103 (2006). (Pubitemid 44292182)
37. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291(23), 2821-2827 (2004). (Pubitemid 38747801)
38. Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117(12), 1537-1544 (2008). (Pubitemid 351440642)
39. Thompson JF, Hyde CL, Wood LS et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ. Cardiovasc. Genet. 2(2), 173-181 (2009).
40. Singer JB, Holdaas H, Jardine AG et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J. Lipid Res. 48(9), 2072-2078 (2007). (Pubitemid 47360627)
41. Polisecki E, Muallem H, Maeda N et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 200(1), 109-114 (2008).
42. Yamamoto A, Kamiya T, Yamamura T et al. Clinical features of familial hypercholesterolemia. Arteriosclerosis 9(Suppl. 1), I66-I74 (1989). (Pubitemid 19046969)
43. Couture P, Brun LD, Szots F et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18(6), 1007-1012 (1998). (Pubitemid 28272598)
44. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet. Genomics 15(4), 219-225 (2005). (Pubitemid 40569893)
45. Kajinami K, Yagi K, Higashikata T, Inazu A, Koizumi J, Mabuchi H. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am. J. Cardiol. 82(1), 113-117 (1998). (Pubitemid 28322042)
46. Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5(6), 352-358 (2005).
47. Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J. Intern. Med. 266(6), 507-519 (2009).
48. Abifadel M, Rabes JP, Devillers M et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30(4), 520-529 (2009).
49. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4(4), 214-225 (2007). (Pubitemid 46502094)
50. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis. 10, 38 (2011).
51. Naoumova RP, Tosi I, Patel D et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 25(12), 2654-2660 (2005). (Pubitemid 43732293)
52. Pisciotta L, Sallo R, Rabacchi C, Wunsch A, Calandra S, Bertolini S. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr. Metab. Cardiovasc. Dis. 22(10), 831-835 (2012).
53. Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J. Am. Coll. Cardiol. 45(10), 1611-1619 (2005). (Pubitemid 40704495)
54. Norata GD, Garlaschelli K, Grigore L et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 208(1), 177-182 (2010).
55. Kotowski IK, Pertsemlidis A, Luke A et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78(3), 410-422 (2006). (Pubitemid 43291224)
56. Peters BJ, Pett H, Klungel OH et al. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis 217(2), 458-464 (2011).
57. Nieminen T, Kahonen M, Viiri LE, Gronroos P, Lehtimaki T. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 9(10), 1475-1486 (2008).
58. Voora D, Shah SH, Reed CR et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ. Cardiovasc. Genet. 1(2), 100-106 (2008).
59. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 29(9), 1310-1315 (2009).
60. Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein e4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 101(12), 1366-1371 (2000). (Pubitemid 30169856)
61. Chiodini BD, Franzosi MG, Barlera S et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur. Heart J. 28(16), 1977-1983 (2007). (Pubitemid 47579537)
62. Schnapp BJ. Trafficking of signaling modules by kinesin motors. J. Cell Sci. 116(Pt 11), 2125-2135 (2003). (Pubitemid 36722359)
63. Morrison AC, Bare LA, Chambless LE et al. Prediction of coronary heart disease risk using a genetic risk score: the atherosclerosis risk in communities study. Am. J. Epidemiol. 166(1), 28-35 (2007). (Pubitemid 47234300)
64. Shiffman D, Chasman DI, Zee RY et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J. Am. Coll. Cardiol. 51(4), 444-448 (2008).
65. Iakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 51(4), 449-455 (2008).
66. Iakoubova OA, Tong CH, Rowland CM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 51(4), 435-443 (2008).
67. Assimes TL, Holm H, Kathiresan S et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J. Am. Coll. Cardiol. 56(19), 1552-1563 (2010).
68. Hoffmann MM, Marz W, Genser B, Drechsler C, Wanner C. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis 219(2), 659-662 (2011).
69. Ridker PM, MacFadyen JG, Glynn RJ, Chasman DI. Kinesin-like protein 6 (KIF6 ) polymorphism and the efficacy of rosuvastatin in primary prevention. Circ. Cardiovasc. Genet. 4(3), 312-317 (2011).
70. Hopewell JC, Parish S, Clarke R et al. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J. Am. Coll. Cardiol. 57(20), 2000-2007 (2011).
71. Arsenault BJ, Boekholdt SM, Hovingh GK et al. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ. Cardiovasc. Genet. 5(1), 51-57 (2012).
72. Marciante KD, Durda JP, Heckbert SR et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 21(5), 280-288 (2011).
73. Isackson PJ, Ochs-Balcom HM, Ma C et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle Nerve 44(4), 531-538 (2011).
74. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 5(2), 257-264 (2012).
75. Deshmukh HA, Colhoun HM, Johnson T et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. Lipid Res. 53(5), 1000-1011 (2012).
76. Hopewell JC, Parish S, Offer A et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur. Heart J. 34(13), 982-992 (2012).
77. Barber MJ, Mangravite LM, Hyde CL et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE 5(3), e9763 (2010).
78. Chu AY, Guilianini F, Barratt BJ, Nyberg F, Chasman DI, Ridker PM. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. Circ. Cardiovasc. Genet. 5(1), 58-65 (2012).
79. Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375(9725), 1536-1544 (2010).
80. Chu AY, Guilianini F, Grallert H et al. Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. Circ. Cardiovasc. Genet. 5(6), 676-685 (2012).
81. Shiffman D, Trompet S, Louie JZ et al. Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. PLoS ONE 7(5), e38240 (2012).
82. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 8, 415-427 (2012).
83. Leiter LA, Betteridge DJ, Farnier M et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes. Metab. 13(7), 615-628 (2011).
84. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug an update after 4 years. Curr. Vasc. Pharmacol. 9(1), 62-86 (2011).
85. Pisciotta L, Fasano T, Bellocchio A et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 194(2), e116-e122 (2007). (Pubitemid 47513100)
86. Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 4, 16 (2005).
87. Simon JS, Karnoub MC, Devlin DJ et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86(6), 648-656 (2005). (Pubitemid 41752945)
88. Berthold HK, Laaksonen R, Lehtimaki T, Gylling H, Krone W, Gouni-Berthold I. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp. Clin. Endocrinol. Diabetes 116(5), 262-267 (2008). (Pubitemid 351798733)
89. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther. 126(3), 314-345 (2010).
90. Perez-Martinez P, Corella D, Shen J et al. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am. J. Clin. Nutr. 89(1), 391-399 (2009).
91. Cardona F, Guardiola M, Queipo-Ortuno MI, Murri M, Ribalta J, Tinahones FJ. The-1131T C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis 206(1), 148-152 (2009).
92. Lai CQ, Arnett DK, Corella D et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler. Thromb. Vasc. Biol. 27(6), 1417-1425 (2007). (Pubitemid 46809433)
93. Smith JA, Arnett DK, Kelly RJ et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur. J. Hum. Genet. 16(5), 603-613 (2008). (Pubitemid 351594127)
94. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255-2267 (2011).
95. Hu M, Chu WC, Yamashita S et al. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J. Lipid Res. 53(4), 802-809 (2012).
96. Brautbar A, Covarrubias D, Belmont J et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 219(2), 737-742 (2011).
97. Brautbar A, Virani SS, Belmont J, Nambi V, Jones PH, Ballantyne CM. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J. Lipid Res. 53(3), 556-560 (2012).
98. Wilke RA, Ramsey LB, Johnson SG et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112-117 (2012).
99. Cordero P, Ashley EA. Whole-genome sequencing in personalized therapeutics. Clin. Pharmacol. Ther. 91(6), 1001-1009 (2012).
100. Liu Y, Ordovas JM, Gao G et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet. Genomics 19(2), 161-169 (2009).
101. Wojczynski MK, Gao G, Borecki I et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. J. Lipid Res. 51(11), 3316-3323 (2010).
102. Irvin MR, Kabagambe EK, Tiwari HK et al. Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ. Cardiovasc. Genet. 3(5), 462-467 (2010).
103. Christidis DS, Liberopoulos EN, Kakafika AI et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J. Cardiovasc. Pharmacol. Ther. 11(3), 211-221 (2006). (Pubitemid 44536190)
104. Brisson D, Ledoux K, Bosse Y et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor a and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 12(4), 313-320 (2002). (Pubitemid 34620659)
105. Shen J, Arnett DK, Parnell LD et al. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate. J. Cardiovasc. Pharmacol. 59(3), 254-259 (2012).
106. Brouillette C, Bosse Y, Perusse L, Gaudet D, Vohl MC. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J. Hum. Genet. 49(8), 424-432 (2004). (Pubitemid 39243749)
107. Chien KL, Lin YL, Wen HC et al. Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment. Pharmacogenomics 10(2), 267-276 (2009).
108. Liu Y, Ordovas JM, Gao G et al. The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. J. Hum. Genet. 53(8), 709-717 (2008).
109. Foucher C, Rattier S, Flavell DM et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors a G/C intron7 polymorphism in subjects with Type 2 diabetes. Pharmacogenetics 14(12), 823-829 (2004). (Pubitemid 40054337)
110. Shen J, Arnett DK, Parnell LD et al. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care 31(5), 910-915 (2008).
111. Aslibekyan S, Kabagambe EK, Irvin MR et al. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the genetics of lipid lowering drug and diet network. Pharmacogenet. Genomics 22(3), 191-197 (2012).